<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Forth, Victoria E.</style></author><author><style face="normal" font="default" size="100%">Cardet, Juan Carlos</style></author><author><style face="normal" font="default" size="100%">Chang, Ku-Lang</style></author><author><style face="normal" font="default" size="100%">Ericson, Brianna</style></author><author><style face="normal" font="default" size="100%">Hurley, Laura P.</style></author><author><style face="normal" font="default" size="100%">Maher, Nancy E.</style></author><author><style face="normal" font="default" size="100%">Staton, Elizabeth W.</style></author><author><style face="normal" font="default" size="100%">Sosa, Bonnie Telón</style></author><author><style face="normal" font="default" size="100%">Israel, Elliot</style></author><author><style face="normal" font="default" size="100%">on behalf of the PREPARE investigators</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">What Patients Call Their Inhalers Is Associated with “Asthma Attacks”</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of the American Board of Family
                Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023-08-09 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">650-661</style></pages><doi><style  face="normal" font="default" size="100%">10.3122/jabfm.2022.220270R2</style></doi><volume><style face="normal" font="default" size="100%">36</style></volume><issue><style face="normal" font="default" size="100%">4</style></issue><abstract><style  face="normal" font="default" size="100%">Background: Clinician-patient miscommunication contributes to worse asthma outcomes. What patients call their asthma inhalers and its relationship with asthma morbidity are unknown.Methods: Inhaler names were ascertained from Black and Latinx adults with moderate-severe asthma and categorized as “standard” if based on brand/generic name or inhaler type (i.e., controller vs. rescue) or “non-standard” for other terms (i.e., color, device type, e.g., “puffer,” or unique names). Clinical characteristics and asthma morbidity measures were evaluated at baseline: self-reported asthma exacerbations one year before enrollment (i.e., systemic corticosteroid bursts, emergency department (ED)/urgent care (UC) visits, or hospitalizations), and asthma control and quality of life. Multivariable regression models tested the relationship between non-standard names and asthma morbidity measures, with adjustments.Results: Forty-four percent (502/1150) of participants used non-standard inhaler names. These participants were more likely to be Black (p=0.006), from the Southeast (p&lt;0.001), and have fewer years with asthma (p=0.012) relative to those who used standard names. Non-standard inhaler names was associated with an incidence rate ratio (IRR) of 1.29 (95% confidence interval [CI], 1.11-1.50, p=0.001; 1.8 vs. 1.5 events) for corticosteroid bursts for asthma, an IRR=1.43 (95% CI, 1.21-1.69, p&lt;0.001; 1.9 vs. 1.4 events) for ED/UC visits for asthma, and an odds ratio=1.57 (95% CI, 1.12-2.18, p=0.008; 0.5 vs. 0.3 events) for asthma hospitalizations after adjustment.Conclusions: Patients who use non-standard names for asthma inhalers experience increased asthma morbidity. Ascertaining what patients call their inhalers may be a quick method to identify those at higher risk of poor outcomes.</style></abstract></record></records></xml>